News|Videos|September 28, 2023
Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)
Author(s)Giselle Sholler, MD, Anurag Agrawal, MD
Key opinion leaders address the treatment of recurrent or relapsed high-risk neuroblastoma, emphasizing the efficacy of antibody therapies naxitamab and dinutuximab, which target neuroblastoma cells, and the significance of post-induction therapy to enhance patient outcomes before transplantation.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.
Bringing some or all clinical trial-related activities directly to patients can help overcome barriers that prevent many people from participating.
Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.
Alpha DaRT plus pembrolizumab produced responses in all evaluable elderly patients with PD-L1–positive recurrent/metastatic head and neck cancer.
High CR/CRi rates were shown for olverembatinib plus blinatumomab in relapsed/refractory Ph-positive chronic myeloid leukemia and B-ALL.
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
4
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
5